Idorsia Valuation

Is IDIAZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDIAZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IDIAZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDIAZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDIAZ?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for IDIAZ. This is calculated by dividing IDIAZ's market cap by their current preferred multiple.
What is IDIAZ's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CHF 370.38m

IDIAZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	9.1x
Enterprise Value/EBITDA	-3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does IDIAZ's PS Ratio compare to its peers?

The above table shows the PS ratio for IDIAZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.3x
AVCT Avacta Group	6.9x	10.8%	UK£160.5m
OXB Oxford Biomedica	3.5x	19.8%	UK£315.8m
BVXP Bioventix	17x	7.2%	UK£231.0m
GNS Genus	1.6x	5.1%	UK£1.1b
IDIAZ Idorsia	2.6x	33.2%	CHF 370.4m

Price-To-Sales vs Peers: IDIAZ is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (7.3x).

Price to Earnings Ratio vs Industry

How does IDIAZ's PE Ratio compare vs other companies in the GB Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: IDIAZ is good value based on its Price-To-Sales Ratio (2.6x) compared to the European Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is IDIAZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDIAZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.6x
Fair PS Ratio	1.3x

Price-To-Sales vs Fair Ratio: IDIAZ is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDIAZ forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CHF 2.02	CHF 1.69 -16.0%	31.1%	CHF 2.60	CHF 1.00	n/a	8
Jun ’25	CHF 2.61	CHF 1.69 -35.2%	31.1%	CHF 2.60	CHF 1.00	n/a	8
May ’25	CHF 1.82	CHF 1.72 -5.4%	32.0%	CHF 2.60	CHF 1.00	n/a	8
Apr ’25	CHF 2.85	CHF 2.10 -26.4%	41.1%	CHF 4.00	CHF 1.00	n/a	8
Mar ’25	CHF 2.00	CHF 2.07 +3.2%	41.7%	CHF 4.00	CHF 1.00	n/a	8
Feb ’25	CHF 1.47	CHF 2.07 +40.3%	41.7%	CHF 4.00	CHF 1.00	n/a	8
Jan ’25	CHF 2.13	CHF 2.07 -2.8%	41.7%	CHF 4.00	CHF 1.00	n/a	8
Dec ’24	CHF 2.17	CHF 2.63 +21.2%	64.5%	CHF 6.50	CHF 1.00	n/a	8
Nov ’24	CHF 1.71	CHF 4.24 +147.8%	79.2%	CHF 12.00	CHF 1.00	n/a	8
Oct ’24	CHF 2.61	CHF 6.38 +144.4%	36.3%	CHF 12.00	CHF 4.00	n/a	8
Sep ’24	CHF 5.20	CHF 6.28 +20.8%	35.1%	CHF 12.00	CHF 4.00	n/a	9
Aug ’24	CHF 6.76	CHF 5.79 -14.3%	13.1%	CHF 6.50	CHF 4.20	n/a	7
Jul ’24	CHF 6.44	CHF 10.91 +69.4%	62.8%	CHF 30.00	CHF 6.00	n/a	10
Jun ’24	CHF 7.96	CHF 13.72 +72.4%	57.0%	CHF 30.00	CHF 7.00	CHF 2.61	9
May ’24	CHF 8.60	CHF 13.46 +56.5%	56.6%	CHF 30.00	CHF 6.00	CHF 1.82	10
Apr ’24	CHF 9.96	CHF 15.23 +53.0%	39.7%	CHF 30.00	CHF 9.00	CHF 2.85	11
Mar ’24	CHF 12.75	CHF 15.23 +19.5%	39.7%	CHF 30.00	CHF 9.00	CHF 2.00	11
Feb ’24	CHF 15.22	CHF 17.43 +14.5%	39.2%	CHF 36.00	CHF 10.00	CHF 1.47	11
Jan ’24	CHF 13.52	CHF 18.17 +34.4%	39.1%	CHF 36.00	CHF 10.00	CHF 2.13	11
Dec ’23	CHF 14.31	CHF 19.65 +37.3%	35.0%	CHF 36.00	CHF 10.00	CHF 2.17	11
Nov ’23	CHF 16.15	CHF 19.71 +22.1%	34.8%	CHF 36.00	CHF 10.00	CHF 1.71	10
Oct ’23	CHF 12.72	CHF 22.91 +80.1%	33.2%	CHF 36.00	CHF 10.00	CHF 2.61	10
Sep ’23	CHF 14.36	CHF 24.92 +73.6%	25.4%	CHF 36.00	CHF 15.00	CHF 5.20	11
Aug ’23	CHF 11.59	CHF 25.01 +115.8%	25.3%	CHF 36.00	CHF 15.00	CHF 6.76	11
Jul ’23	CHF 13.49	CHF 26.56 +96.9%	20.9%	CHF 36.00	CHF 17.00	CHF 6.44	11
Jun ’23	CHF 15.63	CHF 26.56 +69.9%	20.9%	CHF 36.00	CHF 17.00	CHF 7.96	11

Analyst Forecast: Target price is lower than the current share price.